Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.

摘要: The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe an inhaled corticosteroid (ICS) or ICS/long-acting beta2-agonist (LABA) combination a short-acting (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, large proportion still fail achieve guideline-defined control, overuse SABA medication expense ICS commonly observed. New simplified treatment approaches may offer solution assist physicians overall control. One such approach, which recommended in GINA guidelines, budesonide/formoterol both therapy. This strategy significantly reduces rate exacerbations compared ICS/LABA plus achieves equivalent daily symptom higher doses separate relief. These benefits are achieved lower steroid load, therapy well tolerated asthma. review discusses current management disease examines evidence alternative approaches.